CBD and chronic pain

Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB:INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the...